Physician profile
Anthony Guerrino
NPI 1023073103
$9,565.21
in general payments reported to CMS, 2019-2025
31 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,958 · 2020: $301 · 2021: $609 · 2022: $802 · 2023: $444 · 2024: $206 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.13 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,688.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,195.27 | 2019-2025 | Fasenra, Breztri |
| Glaxosmithkline, LLC. | $660.86 | 2019-2025 | Nucala, Arexvy |
| Insmed, INC. | $406.13 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $341.63 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $318.08 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $221.57 | 2022-2023 | Dupixent |
| Janssen Pharmaceuticals, INC | $219.69 | 2019 | |
| Genentech USA, INC. | $215.89 | 2019 | |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Mylan Specialty L.P. | $121.38 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $121.22 | 2019-2020 | |
| Abbott Laboratories | $114.99 | 2019 | |
| Amgen INC. | $114.27 | 2019 | |
| Pulmonx Corporation | $94.87 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $87.81 | 2019-2020 | |
| Corcept Therapeutics | $86.08 | 2019 | |
| Shire North American Group INC | $85.65 | 2019 | |
| Grifols USA, LLC | $58.57 | 2019-2021 | |
| Electromed, INC. | $47.08 | 2019 | |
| Mallinckrodt Enterprises LLC | $45.56 | 2019 | |
| Gilead Sciences, INC. | $35.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.65 | 2020 | |
| Pfizer INC. | $24.65 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.81 | 2019 | |
| United Therapeutics Corporation | $18.08 | 2021 | |
| Seqirus USA INC | $17.16 | 2019 | |
| Ibsa Pharma INC. | $13.54 | 2019 | |
| Novo Nordisk INC | $13.18 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.17 | 2019 | |
| Lilly USA, LLC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Guerrino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.